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Abstract Teriflunomide is a once-daily oral agent that
has been licensed in the EU since August 2013 for the
treatment of adult patients with relapsing–remitting mul-
tiple sclerosis (RRMS). More recently (September 2014),
the EU summary of product characteristics (SmPC) was
updated to include data from patients with a first clinical
demyelinating event. This review examines the EU SmPC
for teriflunomide, with reference to key clinical and safety
outcomes and practical considerations for prescribing
physicians. In two phase III trials (TEMSO and TOWER)
in patients with relapsing forms of MS, teriflunomide
14 mg significantly reduced the annualized relapse rate and
the risk of confirmed disability progression sustained for at
least 12 weeks. Magnetic resonance imaging (MRI) total
lesion volume, gadolinium-enhancing lesions, and unique
active lesions were reduced with teriflunomide treatment in
TEMSO. In the TOPIC study, in patients with a first
clinical demyelinating event, teriflunomide treatment sig-
nificantly reduced the time to a second clinical episode
(relapse). Across the clinical studies, teriflunomide was
generally well tolerated; adverse events reported in C10 %
of teriflunomide-treated patients were diarrhea, nausea,
increased alanine aminotransferase, and alopecia. Data
from the clinical development program support the use of
teriflunomide in a broad spectrum of patients with RRMS.
Key Points
Teriflunomide is a once-daily oral treatment
approved for relapsing–remitting multiple sclerosis.
Teriflunomide has pleiotropic and novel mechanisms
of action, specifically targeting activated T and B
cells.
Teriflunomide demonstrated consistent efficacy in
reducing the risk of disability progression and the
annualized relapse rate in two independent phase III
trials (TEMSO, TOWER) as well as positive
outcomes on several magnetic resonance imaging
(MRI) parameters of disease activity (TEMSO).
1 Introduction
Teriflunomide (Aubagio, sanofi-aventis groupe, Paris,
France) is a once-daily oral agent that was approved in the
EU in August 2013 for the treatment of adult patients with
relapsing–remitting multiple sclerosis (RRMS) [1]. It was
the second oral disease-modifying therapy (DMT), fol-
lowing fingolimod (Gilenya, Novartis Europharm Ltd,
UK), approved in the EU for the treatment of RRMS in
March 2011 [2]. Fingolimod is approved for use in patients
with high disease activity despite treatment with at least
one DMT, or in patients with rapidly evolving severe
RRMS. The 14-mg dose of teriflunomide is licensed in the
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EU and several other countries. BG-12 (Tecfidera, Biogen
Idec Ltd, UK) has also been approved for patients with
RRMS [3].
Teriflunomide’s mechanism of action is considered to be
related to its effect on rapidly dividing lymphocytes.
Teriflunomide selectively and reversibly inhibits a key
mitochondrial enzyme, dihydroorotate dehydrogenase
(DHODH), required for de novo pyrimidine synthesis. As a
consequence of limited de novo pyrimidine production,
teriflunomide reduces the proliferation of activated T and B
cells, which are thought to participate in the inflammatory
process in the central nervous system [4]. In vitro, teri-
flunomide causes cell-cycle arrest without cell death [5, 6],
and the cytostatic effects of teriflunomide can be reversed
by the addition of exogenous uridine [6], which supports
DHODH inhibition as the primary mechanism. However,
pleiotropic effects independent from DHODH inhibition
have also been reported [4]. Investigation of the effects of
teriflunomide on peripheral blood mononuclear cells
in vitro have shown little or no impact on lymphocyte
activation and no cytotoxicity associated with terifluno-
mide [7]. Resting lymphocytes rely on the salvage path-
way, which is unaffected by teriflunomide, to meet their
pyrimidine needs, thereby preserving these cells for normal
immune surveillance. In a study of teriflunomide’s effect
on the immune response to seasonal influenza vaccine,
patients with relapsing forms of MS (RMS) receiving
teriflunomide generally mounted appropriate memory
immune responses to influenza vaccination [8]. In a sepa-
rate study, teriflunomide-treated healthy volunteers were
able to make a seroprotective response to neoantigen (ra-
bies vaccine) [9]. Together, these results argue against a
clinically relevant immunosuppressive effect.
Teriflunomide is the active metabolite of leflunomide
(ARAVA, Sanofi-Aventis Deutschland GmbH, Ger-
many), a disease-modifying antirheumatic drug (DMARD)
licensed in the EU since 1999 for the treatment of adult
patients with active rheumatoid arthritis (RA) [10]. Post-
marketing experience with leflunomide has informed the
EU summary of product characteristics (SmPC) for teri-
flunomide, specifically regarding safety as reflected in
warnings and precautions for use. However, there are a
number of challenges when comparing the safety of teri-
flunomide with its parent compound; leflunomide has only
been evaluated in patients with RA, who often have
comorbidities and are prescribed concomitant medications,
which may impact the safety observations on leflunomide
and confound comparisons with teriflunomide. There are
also pharmacological differences between leflunomide and
teriflunomide, which are discussed below.
This review summarizes key efficacy and safety data
that supported the approval of teriflunomide 14 mg for the
once-daily treatment of RRMS. It specifically focuses on
recommendations in the EU SmPC in the context of clin-
ical practice, with the aim of providing a practical refer-
ence for treatment.
2 Key Data from Teriflunomide Trials
2.1 Efficacy Outcomes
The efficacy of teriflunomidewas demonstrated in three phase
III, placebo-controlled trials, TEMSO (NCT00134563)
[1, 11], TOWER (NCT00751881) [1, 12], and TOPIC
(NCT00622700) [1, 13] (Table 1), and in one active com-
parator phase III trial, TENERE (NCT00883337) [1, 14].Data
pertaining to the 14-mg dose have been emphasized here as it
is the dose licensed in the EU.
In the TEMSO trial, 1088 patients with RMS (McDon-
ald 2001 criteria [15]) were randomized to receive once-
daily oral teriflunomide 14 mg, teriflunomide 7 mg, or
placebo for 108 weeks [1, 11]. Teriflunomide 14 mg sig-
nificantly reduced annualized relapse rate (ARR) (primary
endpoint) by 31.5 % (p\ 0.001) and reduced the risk of
disability progression (key secondary endpoint) by 30.0 %
(p\ 0.05) versus placebo (Table 2). Teriflunomide 14 mg
also reduced total lesion volume [key magnetic resonance
imaging (MRI) endpoint] by 67 % versus placebo at week
108 (p\ 0.001), the mean number of T1 gadolinium (Gd)-
enhancing lesions per scan by a change relative to placebo
of 0.80 (p\ 0.0001) and the number of unique active
lesions per scan by 69 % (p\ 0.0001) (Table 2).
In a post hoc analysis of a subgroup of patients from the
TEMSO study with high disease activity (two or
more relapses in 1 year and with one or more Gd-en-
hancing lesion on baseline brain MRI; n = 127), a con-
sistent treatment effect of teriflunomide 14 mg compared
with placebo was observed for ARR and disability pro-
gression [1, 16].
In TOWER, 1169 patients with RMS (McDonald 2005
criteria [17]) were randomized to receive teriflunomide
14 mg, 7 mg, or placebo (Table 1) [1, 12]. The 14-mg dose
significantly reduced ARR by 36.0 % (p\ 0.0001) and the
risk of confirmed disability progression sustained for
3 months by 32.0 % (p\ 0.05) versus placebo (Table 2).
In TOPIC, 618 patients with a first clinical demyeli-
nating event were randomized to receive teriflunomide
14 mg, 7 mg, or placebo for up to 108 weeks. Terifluno-
mide 14 mg significantly reduced the risk of a second
relapse by 43 % compared with placebo (p = 0.0087), and
the risk of relapse or new MRI lesion, whichever occurred
first, by 35 % (p = 0.0003). Significant efficacy on MRI
outcomes (total lesion volume, number and volume of Gd-
enhancing lesions, and volume of post-Gd T1 lesion
component) was also demonstrated [1, 13].
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The effectiveness of teriflunomide was compared with
that of subcutaneous interferon (IFN)-b-1a in the phase III
TENERE study, in which 324 randomized patients were
treated for at least 48 weeks. No difference was found
between teriflunomide and IFNb on the primary endpoint
of time to failure, defined as confirmed relapse or perma-
nent treatment discontinuation, whichever came first.
Overall, patients reported greater treatment satisfaction and
less fatigue with teriflunomide than with IFNb [1, 14, 16].
2.2 Safety and Tolerability Outcomes
The safety analysis included 2047 teriflunomide-treated
patients from four placebo-controlled trials: phase II
(NCT00475865) [18], TEMSO, TOWER, and TOPIC.
Adverse events reported in C10 % of patients treated with
teriflunomide were diarrhea, nausea, increased alanine
aminotransferase (ALT), and alopecia (reported as hair
thinning). In general, diarrhea, nausea, and hair thinning
were mild to moderate in intensity, transient, and only
infrequently led to treatment discontinuation (Table 3) [1].
Mild increases in ALT B39 the upper limit of normal
(ULN) were more frequently observed in patients receiving
teriflunomide (49.6 %) than in those receiving placebo
(29.5 %). According to study protocols, patients with
confirmed ALT [39 ULN were required to discontinue
treatment permanently [14]. The frequency of ALT increase
[39 ULN was similar across treatment groups. Increases
Table 1 Overview of placebo-controlled trials for teriflunomide
Phase II POC [18] TEMSO [11] TOWER [12] TOPIC [13]
Study design Randomized (1:1:1), double-blind, placebo-controlled
Study
duration
36 weeks 108 weeks 48 weeks after the last
patient randomized
Up to 108 weeks
Study
population
• Poser criteria for MS [23]
• Aged 18–65 years
• EDSS B6.0
• Two documented relapses in
the previous 3 years and one
relapse in the past year
• McDonald 2001 criteria
for MS with relapsing
course ± progression [15]
• Aged 18–55 years
• EDSS B5.5
• C2 clinical relapses in the
previous 2 years or C1
relapse in the past year
• No relapse in 60 days
prior to randomization
• McDonald 2005 criteria
for MS with relapsing
course ± progression
[17]
• Aged 18–55 years
• EDSS B5.5
• C2 clinical relapses in
the previous 2 years or
C1 relapse in the past
year
• No relapse in 30 days
prior to randomization
• First acute or subacute, well-
defined neurological event
consistent with demyelination
(optic neuritis confirmed by an
ophthalmologist, spinal cord
syndrome, brainstem/cerebellar
syndromes)
• Onset of MS symptoms
occurring within 90 days of
randomization
• C2 T2 lesions C3 mm in
diameter that are characteristic of
MS
Treatment
armsa
• Teriflunomide 14 mg/day
(n = 57)
• Teriflunomide 7 mg/day
(n = 61)
• Placebo (n = 61)
• Teriflunomide 14 mg/day
(n = 358)
• Teriflunomide 7 mg/day
(n = 365)
• Placebo (n = 363)
• Teriflunomide 14 mg/day
(n = 370)
• Teriflunomide 7 mg/day
(n = 407)
• Placebo (n = 388)
• Teriflunomide 14 mg/day
(n = 216)
• Teriflunomide 7 mg/day
(n = 205)
• Placebo (n = 197)
Primary
endpoint
Mean number of combined
unique active lesions per
MRI scan
Annualized relapse rate Time to relapse indicating
conversion to clinically definite
MS
Key
secondary
endpoint(s)
• Other MRI measuresb
• Annualized relapse rate
• Disability progression
• Confirmed disability
progression sustained
C3 months
• MRI total lesion volume
• Mean number of Gd-
enhancing lesions on T1-
weighted images per MRI
scan
• Confirmed disability
progression sustained
C3 months
• Time to relapse or new MRI
lesion, whichever occurred first
EDSS Expanded Disability Status Scale, Gd gadolinium, MRI magnetic resonance imaging, MS multiple sclerosis, POC proof of concept
a All randomized patients who received one or more dose of study medication
b Other MRI outcomes measured: number of T1 enhancing lesions and T2 active lesions, the number of patients with combined unique active
lesions, and the percentage change from baseline in the T2 lesion volume
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in ALT occurred mainly within the first 6 months of
treatment, and the majority of these increases were rever-
sible following discontinuation of treatment [1].
Minor reductions (\15 % decrease from baseline levels)
in white blood cells (WBCs), mainly neutrophils and
lymphocytes, have been observed in patients receiving
teriflunomide in clinical trials. Most reductions were
observed during the first 6 weeks of treatment with no
further decrease while patients remained on therapy [1].
No increase in the incidence of serious infections was
observed for teriflunomide (2.7 %) compared with placebo
(2.2 %); serious opportunistic infections occurred in 0.2 %
of patients per group [1]. There was no increased risk of
malignancy with teriflunomide treatment [1].
Peripheral neuropathy, including both polyneuropathy
and mononeuropathy (e.g., carpal tunnel syndrome), was
reported more frequently in patients receiving terifluno-
mide than in placebo patients. In the pivotal studies, the
incidence of peripheral neuropathy confirmed by nerve
conduction studies was 1.4 % (13 of 1002 patients) in the
teriflunomide group compared with 0.4 % (4 of 997
patients) in the placebo group [1].
Systolic blood pressure [140 and [160 mmHg was
observed in 19.9 and 3.8 % of patients receiving teri-
flunomide compared with 15.5 and 2.0 % of those receiv-
ing placebo, respectively. Diastolic blood pressure
[90 mmHg was observed in 21.4 % of patients receiving
teriflunomide compared with 13.6 % of patients receiving
placebo [1].
3 Practical Considerations for Physicians
Prescribing Teriflunomide
Physicians must be aware of required assessments
before initiation of treatment and monitoring require-
ments during teriflunomide therapy, as well as con-
traindications for its use (Tables 4, 5). In addition to
Table 2 Efficacy outcomes from key registration trials
TEMSO TOWER
Teriflunomide
14 mg (n = 358)
Placebo
(n = 363)
Teriflunomide
14 mg (n = 370)
Placebo
(n = 388)
Annualized relapse rate 0.37 0.54 0.32 0.50
Relative reduction vs. placebo (%) 31.5*** – 36.0**** –
Patients remaining relapse free at week 108 (%) 56.5 45.6 57.1 46.8
Hazard ratio vs. placebo 0.72** – 0.63**** –
Patients with 3-month sustained disability progression at week 108 (%) 20.2 27.3 15.8 19.7
Hazard ratio vs. placebo 0.70* – 0.68* –
Risk reduction vs. placebo (%) 30.0 – 32.0 –
Patients free of MRI activitya at week 108 (%) 37.6****b
OR 2.26 (1.61–3.17)
21.1 – –
Patients with no evidence of disease activityc at week 108 (%) 21.2***b
OR 2.06 (1.35–3.13)
11.6 – –
Change from baseline in total lesion volume (ml)d at week 108 0.72 2.21 – –
Relative reduction vs. placebo (%) 67.0*** – – –
Mean number of T1 Gd-enhancing lesions per scan 0.38 1.18 – –
Change relative to placebo -0.80**** – – –
Number of unique active lesions per scan 0.75 2.46 – –
Relative reduction vs. placebo (%) 69.0**** – – –
Data in parentheses are 95 % confidence intervals
Gd gadolinium, MRI magnetic resonance imaging, OR odds ratio
* p\ 0.05, ** p\ 0.01, *** p\ 0.001, **** p\ 0.0001
a MRI activity was defined as no Gd-enhancing T1 lesions and no new/enlarging T2 lesions. Evaluable patients must have at least one valid MRI
scan for assessment over the study duration; Placebo, n = 346; 14 mg, n = 340
b Data on file
c No evidence of disease activity was defined as no Gd-enhancing T1 lesions, no new/enlarging T2 lesions, no confirmed clinical relapse, and no
3-month sustained disability progression. Evaluable patients must have both valid MRI and clinical activity assessments over the study duration;
Placebo, n = 346; 14 mg, n = 340
d Total volume of all abnormal brain tissue and calculated as the sum of the total volume of T2 lesion component and T1 hypointense lesion
component
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the EU SmPC recommendations referred to in this
article, national recommendations and guidelines have
been issued.
3.1 Considerations Before Initiation
of Teriflunomide Therapy
Elevations in liver enzymes have been observed in patients
receiving teriflunomide in clinical trials, and teriflunomide
treatment is contraindicated in patients with severe hepatic
impairment [Child–Pugh class C, where A (5–6 points) is
the least severe and C (10–15 points) is the most severe] [1,
19]. ALT/serum glutamic pyruvic transaminase (SGPT)
should be assessed before initiation of teriflunomide treat-
ment [1].
Due to the effect of teriflunomide on WBC counts, a
complete blood count, including differential WBC and
platelet count, should be assessed [1].
Teriflunomide treatment was associated with increases
in systolic and diastolic blood pressure in clinical trials [1,
11, 12] and, therefore, blood pressure should be checked
[1].
Table 3 Frequency of adverse reactions in patients treated with teriflunomide in placebo-controlled trials
System organ classa Very common
(C1/10)
Common
(C1/100 to\1/10)
Uncommon
(C1/1000 to\1/100)
Rare (C1/
10,000
to\1/
1000)
Very rare
(\1/10,000)
Investigations ALT increase Increase: GGT and AST
Decrease: weight, neutrophil
count, WBC count
Gastrointestinal disorders Diarrhea,
nausea
Abdominal pain upper,
vomiting, toothache
Pancreatitisb
Skin and subcutaneous
tissue disorders
Alopecia (hair
thinning)
Rash, acne
Infections and infestations Influenza, upper respiratory
tract infection, urinary tract
infection, bronchitis,
sinusitis, pharyngitis, cystitis,
gastroenteritis viral, oral
herpes, tooth infection,
laryngitis, tinea pedis
Blood and lymphatic system
disorders
Neutropenia, anemia Mild thrombocytopenia
(platelets\100 G/l)
Immune system disorders Mild allergic reactions
Psychiatric disorders Anxiety
Nervous system disorders Paraesthesia, sciatica, carpal
tunnel syndrome
Hyperesthesia, neuralgia,
peripheral neuropathy
Vascular disorders Hypertension
Respiratory, thoracic and
mediastinal disorders
Interstitial
lung
diseaseb
Musculoskeletal and
connective tissue disorders
Musculoskeletal pain, myalgia
Renal and urinary disorders Pollakiuria
Reproductive system and breast
disorders
Menorrhagia
General disorders and
administration site conditions
Pain
Injury, poisoning and
procedural complications
Post-traumatic pain
ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase, WBC, white blood cell
a Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness
b Based on leflunomide data only
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Teriflunomide is contraindicated in women who are
pregnant or of childbearing potential if not using reliable
contraception, or breast feeding (Table 5). Pregnancy must
be excluded before initiation of teriflunomide in women of
childbearing potential [1].
For a full list of considerations before initiating teri-
flunomide, see Table 4.
3.2 Recommendations During Teriflunomide
Therapy
During treatment with teriflunomide, liver enzymes
should be assessed every 2 weeks during the first
6 months of treatment and every 8 weeks thereafter. In
the US prescribing information, monitoring is required at
least monthly for 6 months after starting treatment [20].
If ALT/SGPT increases 2–39 ULN, weekly monitoring
is advised. Patients with pre-existing liver disease may be
at increased risk of developing elevated liver enzymes
when receiving teriflunomide and should be monitored
closely for signals of liver disease; therapy should be
discontinued if liver injury is suspected and/or if elevated
liver enzymes[39 ULN are confirmed [1]. It is advised
to check patients’ blood pressure periodically during
treatment and any blood pressure elevation should be
appropriately managed [1]. Teriflunomide treatment
should be delayed in patients with severe active infection.
Two clinical studies have demonstrated that vaccination
with inactive neoantigen (rabies vaccine) or recall antigen
(influenza vaccine) were safe and effective during treat-
ment with teriflunomide. The use of live attenuated
vaccines may carry an infection risk and should therefore
be avoided, as is generally suggested in MS (Table 5)
[1].
Women of childbearing age must be advised to use
effective contraception during teriflunomide treatment and
after treatment until teriflunomide plasma concentration is
below 0.02 mg/l [1].
3.3 Recommendations for Treatment-Emergent
Situations During Teriflunomide Therapy
A list of recommended management approaches for treat-
ment-emergent clinical situations during teriflunomide
therapy is summarized in Table 5.
3.3.1 Pregnancy
Teriflunomide is contraindicated in pregnant women, or
women of childbearing potential not using reliable contra-
ception, based on observations of teratogenicity and embryo-
lethality in the offspring of teriflunomide-treated rats and
rabbits. However, in vitro teriflunomide studies showed no
evidence for increased frequency of mutations, and terifluno-
mide did not cause chromosome breakage in vivo [1]. In rats,
teriflunomide administration resulted in a lower sperm count,
but fertility was unaffected. No external malformations were
observed in the offspring of male rats administered terifluno-
mide before mating with untreated female rats [1].
In a prospective trial conducted by The Organization of
Teratology Information Specialists (OTIS) comparing
pregnancies in leflunomide-treated RA patients, RA
patients not exposed to leflunomide, and healthy volun-
teers, leflunomide did not demonstrate any evidence of
increased risk for major birth defects, a specific pattern of
major or minor anomalies, or an increased risk of sponta-
neous abortions [21]. Global teriflunomide pregnancy
registries are collecting prospective data from pregnancies
in the post-marketing setting.
During teriflunomide treatment, women of childbearing
potential should discuss plans to stop or change contra-
ception with their treating physician and notify their
physician if pregnancy is suspected. If the pregnancy test is
positive, the physician and patient must discuss the risk to
the pregnancy, and should discuss initiation of the accel-
erated elimination procedure [1]. Teriflunomide US pre-
scribing information recommends that men wishing to
Table 4 Recommendations before initiation of teriflunomide and during therapy
Before starting teriflunomide During teriflunomide treatment
• Measure liver enzymes • Assess liver enzymes every 2 weeks during the first 6 months of treatment
• Exclude pregnancy and confirm use of reliable
contraception
– Monitor every 8 weeks thereafter or as indicated by signs and symptoms (e.g.,
unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or
dark urine)
• If ALT/SGPT is 2–39 ULN, monitor weekly
• Screen for latent tuberculosis infection
– For positive tuberculosis tests, treat by standard
medical practice prior to therapy
• Check baseline blood pressure • Check blood pressure periodically
• Obtain a recent complete blood count including
differential WBC and platelets
• Do not use live attenuated vaccines
• Wait until resolution of any severe, active infection • Confirm patient uses reliable contraception
ALT alanine aminotransferase, SGPT serum glutamic pyruvate transaminase, ULN upper limit of normal, WBC white blood cell
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Table 5 Recommendations/considerations for treatment-emergent situations during teriflunomide therapy
Treatment-emergent situations Recommendations Rationale
Hepatic Leflunomide/teriflunomide
clinical trialsContraindications
Patients with severe hepatic impairment (Child–Pugh
class C)
Warnings and precautions
Mild to moderate hepatic impairment No dosage adjustment necessary
Liver injury is suspected Discontinue teriflunomide
Elevated liver enzymes ([3 9 ULN) are confirmed Consider discontinuing teriflunomide
Clinical signs and symptoms, such as unexplained nausea,
vomiting, abdominal pain, fatigue, anorexia or jaundice,
and/or dark urine occur
Assess liver enzymes
Blood pressure Leflunomide/teriflunomide
clinical trialsWarnings and precautions
Blood pressure increases Manage elevations appropriately
Infections Leflunomide/teriflunomide
immunomodulationContraindications
Patients with severe, active infection until resolution
Warnings and precautions
Serious infection develops Consider suspending treatment; consider
accelerated elimination; re-assess benefits and
risks prior to re-initiation of therapy
Respiratory Leflunomide
Warnings and precautions
Pulmonary symptoms, such as persistent cough and
dyspnea, develop
Consider discontinuing teriflunomide;
investigate further as appropriate
Hematologic Leflunomide/teriflunomide
immunomodulationContraindications
Patients with significantly impaired bone marrow function or
significant anemia, leucopenia, neutropenia, or
thrombocytopenia
Patients with severe immunodeficiency states (e.g., AIDS)
Warnings and precautions
Clinical signs and symptoms (e.g. infection) warrant further
investigation
Perform complete blood cell count as indicated
Severe hematological reactions, including pancytopenia,
occur
Discontinue teriflunomide and any concomitant
myelosuppressive treatment
Anemia, leucopenia, thrombocytopenia, impaired bone
marrow function or bone marrow suppression occur
Consider accelerated elimination
Hypersensitivities Leflunomide
Contraindications
Patients with severe hypersensitivity to the active substance
or to any of the excipients
Warnings and precautions
Skin and/or mucosal reactions that raise suspicions of severe
generalized major skin reactions (Stevens-Johnson
syndrome or toxic epidermal necrolysis—Lyell’s
syndrome) occur
Discontinue teriflunomide and perform
accelerated elimination; do not re-expose
patient to teriflunomide
Ulcerative stomatitis occurs Discontinue teriflunomide
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father a child should discontinue and undergo an acceler-
ated elimination procedure [20], although no such recom-
mendation is made in the EU SmPC.
4 Pharmacokinetics of Teriflunomide
There are pharmacological differences between lefluno-
mide and its major metabolite teriflunomide, which also
form the basis for the designation of teriflunomide as a new
active substance by the European Medicines Agency [16].
Metabolism of leflunomide does not only generate teri-
flunomide, but other metabolites that may contribute to the
leflunomide-specific safety profile. Teriflunomide is only
moderately metabolized and is the only component detected
in plasma. The primary biotransformation pathway for
teriflunomide is hydrolysis, with oxidation as a minor
pathway [1]; therefore, no dosage adjustment is necessary
for patients with mild, moderate, or severe renal impairment
not undergoing dialysis, or patients with mild or moderate
hepatic impairment [mild, Child–Pugh class A (score 5–6);
moderate, Child–Pugh class B (score 7–9)] [1].
Table 5 continued
Treatment-emergent situations Recommendations Rationale
Peripheral neuropathy Leflunomide/teriflunomide
clinical trialsWarnings and precautions
Peripheral neuropathy is confirmed Consider discontinuing teriflunomide and
performing accelerated elimination
Renal Teriflunomide clinical
trialsContraindications
Patients with severe renal impairment undergoing dialysis
Patients with severe hypoproteinemia (e.g. nephrotic
syndrome)
Warnings and precautions
Mild, moderate or severe renal impairment not undergoing
dialysis
No dosage adjustment necessary
Vaccination Immunomodulatory action
of teriflunomideWarnings and precautions
Live attenuated vaccines may carry risk of infections Avoid use of live attenuated vaccines
Fertility, pregnancy and lactation Leflunomide/teriflunomide
pre-clinical toxicologyContraindications
Pregnant women or women of childbearing potential who are
not using reliable contraception during treatment with
teriflunomide and thereafter as long as its plasma levels are
above 0.02 mg/l
Breast-feeding women
Warnings and precautions
A woman has plans to stop or change contraception Discuss risks and contraception options
Pregnancy is suspected Conduct pregnancy testing
Pregnancy test is positive Discuss risk to pregnancy; rapidly lowering
blood level of teriflunomide by accelerated
elimination may decrease risk to the fetus
A woman wishes to become pregnant Recommend accelerated elimination
Overdose Safety precautions
Warnings and precautions
Overdose of teriflunomide Accelerated elimination
Other Leflunomide
Warnings and precautions
Patient experiences adverse reaction, such as dizziness Advise to refrain from driving cars and using
machines
AIDS acquired immunodeficiency syndrome, ULN upper limit of normal
48 A. Chan et al.
A population pharmacokinetic analysis demonstrated
that there is a slow approach to steady-state concentration
(*100 days). In patients with MS, the median half-life of
teriflunomide was approximately 19 days after repeated
14-mg doses. Teriflunomide is extensively bound to plasma
protein ([99 %) and is mainly distributed in plasma.
Severe hypoproteinemia (e.g., due to nephrotic syndrome)
is therefore a contraindication for treatment with teri-
flunomide. Food does not have a clinically relevant effect
on the pharmacokinetics of teriflunomide [1].
5 Accelerated Elimination of Teriflunomide
Teriflunomide is slowly eliminated from plasma; it takes an
average of 8 months to reach plasma concentration less
than 0.02 mg/L, although individual variation means it
may take up to 2 years. Teriflunomide undergoes
enterohepatic circulation, and the accelerated elimination
process is thought to interrupt reabsorption of teriflunomide
at the intestinal level [1].
Several clinical situations may warrant accelerated
elimination of teriflunomide. It should be implemented
after discontinuation of teriflunomide in instances where
(1) pregnancy is confirmed or (2) skin and/or mucosal
reactions develop that raise suspicions of severe general-
ized major skin reactions (e.g., Stevens–Johnson syndrome
or toxic epidermal necrolysis), which have been reported
with leflunomide but not in clinical trials with terifluno-
mide [1]. Accelerated elimination of teriflunomide should
also be considered after discontinuation of teriflunomide in
cases where a serious infection develops, hematologic
disorders or severe hematologic reactions occur, confirmed
peripheral neuropathy develops, a woman wishes to
become pregnant, or a clinically significant overdose or
toxicity of teriflunomide occurs [1].
Table 6 Pharmacokinetic interactions of teriflunomide on other substances [1]
Drug category Example(s) Effect of teriflunomide Recommendation while on
teriflunomide therapy
CYP1A2 substrate Caffeine, duloxetine, alosetron,
theophylline, tizanidine
• Decrease in mean caffeine Cmax
by 18 %
• Decrease in mean caffeine AUC
by 55 %
• Use CYP1A2 substrates with
caution
• Monitor for decreased efficacy
CYP2C8 substrate Repaglinide, paclitaxel, pioglitazone,
rosiglitazone
• Increase in mean repaglinide
Cmax by 1.7-fold
• Increase in mean repaglinide
AUC by 2.4-fold
• Use CYP2C8 substrates with
caution
CYP2C9 substrate Warfarin • 25 % decrease in peak INR • INR follow-up and monitoring
requireda
OAT3 substrate Cefaclor, benzylpenicillin,
ciprofloxacin, indomethacin,
ketoprofen, furosemide, cimetidine,
methotrexate, zidovudine
• Increase in mean cefaclor Cmax
by 1.43-fold
• Increase in mean cefaclor AUC
by 1.54-fold
• Use OAT3 substrates with
caution
BCRP and/or
OATP1B1/B3
substrates
BCRP: rosuvastatin, methotrexate,
topotecan, sulfasalazine,
daunorubicin, doxorubicin
OATP: simvastatin, atorvastatin,
pravastatin, methotrexate,
nateglinide, repaglinide, rifampicin
• Increase in mean rosuvastatin
Cmax by 2.65-fold
• Increase in mean rosuvastatin
AUC by 2.51-fold
• Rosuvastatin: reduce dose by
50 %
• All other BCRP and OATP1B1/
B3 substrates: use with caution
Combined oral
contraceptives
Ethinylestradiol/levonorgestrel • Increase in mean ethinylestradiol
Cmax by 1.58-fold
• Increase in mean ethinylestradiol
AUC0–24 by 1.54-fold
• Increase in mean levonorgestrel
Cmax by 1.33-fold
• Increase in mean levonorgestrel
AUC0–24 by 1.41-fold
• No adverse impact expected
• Consider when selecting or
adjusting oral contraceptives
treatment used in combination
with teriflunomide
AUC area under the curve, AUC0–24 area under the 24-h concentration–time curve, BCRP breast cancer resistant protein, Cmax maximum
concentration, CYP cytochrome P450, INR international normalized ratio, OAT organic anion transporter, OATP organic anion transporting
polypeptide
a There are no data on interaction with phenprocoumon, which is more commonly used in the EU. Given its similarities to warfarin, close INR
monitoring is also advisable during concomitant phenprocoumon use
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For accelerated elimination, use of cholestyramine 8 g
administered three times daily for 11 days or 50 g of
activated powdered charcoal every 12 h for 11 days are
recommended. Cholestyramine 4 g three times daily can be
used if the higher dose is not well tolerated. All described
regimens have been shown to decrease teriflunomide
plasma concentrations by [98 %, with cholestyramine
being faster than charcoal.
It should be noted that patients receiving oral contra-
ceptives while undergoing accelerated elimination should
use alternative contraceptive methods because cholestyra-
mine and activated charcoal may negatively affect the
absorption of estrogens and progestogens [1].
6 Interaction with Other Medicinal Products
Metabolism studies conducted in vitro have demonstrated
that teriflunomide is not directly metabolized by cyto-
chrome P450 (CYP) or flavine monoxidase enzymes [1],
which limits the potential for drug–drug interactions. This is
a significant factor differentiating teriflunomide from
leflunomide. Furthermore, polymorphisms in CYP 2C19 in
patients with RA were associated with different levels of
metabolism of leflunomide, and poor metabolizers fre-
quently discontinued their treatment due to adverse events
[16, 22]. However, teriflunomide co-administration with
potent CYP and transport inducers may decrease the
amount of teriflunomide exposure and therefore should be
used with caution [1]. A list of pharmacokinetic interactions
of teriflunomide on other substances is shown in Table 6.
No waiting period is required when initiating terifluno-
mide after IFNb or glatiramer acetate, provided there are
no laboratory abnormalities. Due to the relatively long-
lasting biological activity of natalizumab, concomitant
exposure could occur for up to 2–3 months following
discontinuation of natalizumab if teriflunomide therapy
were initiated immediately. Therefore, caution is required
when switching patients from natalizumab to terifluno-
mide. Based on the half-life of fingolimod, a 6-week
interval is needed for clearance from the circulation, and a
period of 1–2 months is commonly needed for lympho-
cytes to return to normal range. Starting teriflunomide
within this interval will result in concomitant exposure to
fingolimod, which may lead to an additive effect on the
immune system [1].
7 Conclusions
Data from the teriflunomide clinical development program
support the positive benefit : risk profile of teriflunomide
14 mg in patients with RRMS when prescribed according
to the SmPC. Teriflunomide demonstrated significant and
consistent efficacy in TEMSO and TOWER. In addition,
positive outcomes on several MRI parameters were
observed in the TEMSO study. In the TOPIC study, teri-
flunomide significantly reduced the risk of relapse in
patients with a first clinical episode suggestive of MS.
These data support the use of teriflunomide in patients in
the early stages of relapsing MS. Teriflunomide has a well-
characterized safety and tolerability profile. An under-
standing of pre-treatment evaluations and on-treatment
monitoring will ensure optimal outcomes when using
teriflunomide in the clinical setting and facilitate identifi-
cation of potential safety concerns as well as provide
guidance for treatment-emergent clinical situations.
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